Cai is focused on how social determinants of health, like lack of insurance and transportation, lead patients with diabetes to have lapses in their ophthalmology care, which decreases the likelihood of prompt intervention and can lead to poor outcomes.

Johnson leads a translational neuroscience laboratory that focuses on stem cell transplantation to regenerate damaged optic nerves. This has the potential to someday restore vision damaged by conditions like eye stroke, or diseases like glaucoma.

Rajaii’s work focuses on understanding thyroid eye disease, specifically how orbital fibroblasts, the target cells in the pathology of thyroid eye disease, differentiate to become fat cells, which causes the expansion of the tissues behind the eye?

Sachdeva is researching risks for diabetic retinopathy, why some patients develop different severities of disease, and how changes in the retina can be addressed earlier so it’s possible to prevent progression — or even reverse it if discovered in time.

As co-founder of Wilmer Eye Institute's Genetic Eye Disease (GEDi) Center, Doyle has centralized ophthalmic genetics services at Wilmer, providing patients with both clinical care, genetic counseling services, and low vision services to assist patients' functioning in daily life.

Shekhawat has partnered with Aravind Eye Hospital in India as well as biomedical engineers and public health researchers at Johns Hopkins to develop a telemedicine platform that will provide virtual eye screenings to rural residents in India.

Carey, dually trained as a neuro-ophthalmologist and retina specialist, is also an outstanding clinician, recently recognized for his skill and empathy with patients with a promotion to John's Hopkins newly-established clinical excellence track.

Yohannan has constructed a new AI algorithm to predict which patients were at risk for rapidly progressing glaucoma that has achieved 90% accuracy.